Aurinia Pharmaceuticals (AUPH) EBIAT: 2014-2025
Historic EBIAT for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Sep 2025 value amounting to $31.6 million.
- Aurinia Pharmaceuticals' EBIAT rose 119.87% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.8 million, marking a year-over-year increase of 445.14%. This contributed to the annual value of $5.8 million for FY2024, which is 107.37% up from last year.
- Latest data reveals that Aurinia Pharmaceuticals reported EBIAT of $31.6 million as of Q3 2025, which was up 46.66% from $21.5 million recorded in Q2 2025.
- In the past 5 years, Aurinia Pharmaceuticals' EBIAT registered a high of $31.6 million during Q3 2025, and its lowest value of -$50.4 million during Q1 2021.
- In the last 3 years, Aurinia Pharmaceuticals' EBIAT had a median value of $722,000 in 2024 and averaged $376,364.
- Per our database at Business Quant, Aurinia Pharmaceuticals' EBIAT crashed by 312.71% in 2021 and then soared by 2,879.64% in 2025.
- Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' EBIAT stood at -$33.3 million in 2021, then rose by 21.84% to -$26.0 million in 2022, then declined by 3.18% to -$26.9 million in 2023, then spiked by 105.32% to $1.4 million in 2024, then spiked by 119.87% to $31.6 million in 2025.
- Its EBIAT stands at $31.6 million for Q3 2025, versus $21.5 million for Q2 2025 and $23.3 million for Q1 2025.